[go: up one dir, main page]

AR045013A1 - METHOD TO TREAT OR PREVENT DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH COMPOUNDS THAT HAVE SELECTIVITY BY THE ALFA -3 SUBUNITY OF THE BENZODIAZEPINAS RECEPTOR - Google Patents

METHOD TO TREAT OR PREVENT DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH COMPOUNDS THAT HAVE SELECTIVITY BY THE ALFA -3 SUBUNITY OF THE BENZODIAZEPINAS RECEPTOR

Info

Publication number
AR045013A1
AR045013A1 ARP040102355A ARP040102355A AR045013A1 AR 045013 A1 AR045013 A1 AR 045013A1 AR P040102355 A ARP040102355 A AR P040102355A AR P040102355 A ARP040102355 A AR P040102355A AR 045013 A1 AR045013 A1 AR 045013A1
Authority
AR
Argentina
Prior art keywords
nervous system
central nervous
disorders
benzodiazepinas
subunity
Prior art date
Application number
ARP040102355A
Other languages
Spanish (es)
Original Assignee
Elbion Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Ag filed Critical Elbion Ag
Publication of AR045013A1 publication Critical patent/AR045013A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de 1-ar(alqu)ilimidazolin-2-onas que contienen un radical amino disustituido en la posición 4, como por ejemplo el 1-(4-clorofenil)-4-piperidinoimidazolin-2-ona, entre otros, para el tratamiento o la prevención de trastornos del sistema nervioso central, incluyendo depresión, ansiedad, trastornos del movimiento y en especial distonía, y trastornos psicóticos, y especialmente esquizofrenia y síntomas psicóticos asociados a otros trastornos mentales. Composiciones farmacéuticas que los contienen.Use of 1-ar (alk) unlimitedzolin-2-ones containing an amino radical disubstituted at position 4, such as 1- (4-chlorophenyl) -4-piperidinoimidazolin-2-one, among others, for the treatment or the prevention of disorders of the central nervous system, including depression, anxiety, movement disorders and especially dystonia, and psychotic disorders, and especially schizophrenia and psychotic symptoms associated with other mental disorders. Pharmaceutical compositions that contain them.

ARP040102355A 2003-07-11 2004-07-02 METHOD TO TREAT OR PREVENT DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH COMPOUNDS THAT HAVE SELECTIVITY BY THE ALFA -3 SUBUNITY OF THE BENZODIAZEPINAS RECEPTOR AR045013A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US48667803P 2003-07-11 2003-07-11

Publications (1)

Publication Number Publication Date
AR045013A1 true AR045013A1 (en) 2005-10-12

Family

ID=34062138

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102355A AR045013A1 (en) 2003-07-11 2004-07-02 METHOD TO TREAT OR PREVENT DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH COMPOUNDS THAT HAVE SELECTIVITY BY THE ALFA -3 SUBUNITY OF THE BENZODIAZEPINAS RECEPTOR

Country Status (17)

Country Link
US (2) US20050032863A1 (en)
EP (2) EP2027856A1 (en)
JP (1) JP2009513539A (en)
KR (1) KR20060032633A (en)
CN (2) CN101254189A (en)
AR (1) AR045013A1 (en)
AU (1) AU2004255414A1 (en)
BR (1) BRPI0412512A (en)
CA (1) CA2531861A1 (en)
MX (1) MXPA05013196A (en)
NO (1) NO20060686L (en)
NZ (1) NZ544251A (en)
RU (1) RU2354377C2 (en)
TW (1) TW200512197A (en)
UA (1) UA87982C2 (en)
WO (1) WO2005004867A2 (en)
ZA (1) ZA200509169B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101802A1 (en) * 2006-03-08 2007-09-13 F. Hoffmann-La Roche Ag 4-amino-1,5-substituted 1,5-dihydro-imidazol-2-ones
CA2773038A1 (en) 2009-09-04 2011-03-10 P. Jeffrey Conn Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
BR112014003061A2 (en) 2011-08-12 2017-02-21 Boehringer Ingelheim Vetmedica Gmbh masked flavor pharmaceutical composition
CN104199105A (en) * 2014-08-27 2014-12-10 中国石油天然气集团公司 Pickup method and device of first arrivals in high-density three-dimensional exploration
WO2018011566A1 (en) * 2016-07-11 2018-01-18 Ranvier Health Limited Method of diagnostic relevance based on taste recognition
US20220288052A1 (en) * 2019-08-06 2022-09-15 Initiator Pharma A/S Compound for combination treatment
KR102489109B1 (en) * 2020-06-02 2023-01-16 부산대학교 산학협력단 Composition for treating dystonia comprising acetylcholine receptor gene variants

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90869C (en) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Process for the preparation of imidazolidinone derivatives useful as a medicament
IL104853A (en) * 1992-02-27 1997-11-20 Yamanouchi Pharma Co Ltd Benzodiazepine derivatives, their preparation and pharmaceutical compositions containing them
US5484944A (en) * 1993-10-27 1996-01-16 Neurogen Corporation Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
AU5884696A (en) 1995-06-23 1997-01-22 Bausch & Lomb Incorporated Method for cleaning contact lenses utilizing polysulfonates
DE19532668A1 (en) * 1995-09-05 1997-03-06 Dresden Arzneimittel Novel, anticonvulsant 1-ar (alk) yl-imidazolin-2-ones which contain a disubstituted amine radical in the 4-position, and process for their preparation
US5869481A (en) * 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
US5861423A (en) * 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
DE19721580A1 (en) * 1997-05-23 1998-11-26 Dresden Arzneimittel Use of 1-ar (alk) yl-imidazolin-2-one for the treatment of anxiety and tension
WO1999037370A1 (en) 1998-01-22 1999-07-29 Precedence Publishing, Inc. Game using collectibles as playing pieces
GB9821179D0 (en) 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
GB9929687D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
GB0018473D0 (en) * 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
GB0122696D0 (en) * 2001-09-20 2001-11-14 Merck Sharp & Dohme Therapeutic agents
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs

Also Published As

Publication number Publication date
US20050032863A1 (en) 2005-02-10
CN101254189A (en) 2008-09-03
EP2027856A1 (en) 2009-02-25
CA2531861A1 (en) 2005-01-20
RU2006104118A (en) 2006-06-10
BRPI0412512A (en) 2006-09-19
NO20060686L (en) 2006-03-14
WO2005004867A3 (en) 2005-04-21
RU2354377C2 (en) 2009-05-10
NZ544251A (en) 2009-12-24
KR20060032633A (en) 2006-04-17
US20080114032A1 (en) 2008-05-15
CN1822836A (en) 2006-08-23
UA87982C2 (en) 2009-09-10
AU2004255414A1 (en) 2005-01-20
WO2005004867A2 (en) 2005-01-20
EP1646386A2 (en) 2006-04-19
MXPA05013196A (en) 2006-03-09
TW200512197A (en) 2005-04-01
JP2009513539A (en) 2009-04-02
ZA200509169B (en) 2006-07-26

Similar Documents

Publication Publication Date Title
CU23464B7 (en) (1,8) NAFTIDIRIN-2-ONAS AND RELATED COMPOUNDS FOR THE TREATMENT OF CHICHOPHRENIA
ECSP067021A (en) COMPOUNDS AND COMPOSITIONS AS RECEPTOR MODULATORS ACTIVATED BY PEROXISOM PROLIFERATOR (PPAR)
PA8675701A1 (en) NEW DERIVATIVES OF FLUORENE, COMPOSITIONS THAT CONTAIN THEM AND ITS USE
ECSP055535A (en) DERIVATIVES OF 1-HETEROCICLIALQUIL-3-SULFONILAZAINDOL OR AZAINDOL AS 5-HYDROXITRIPTAMINE-6 LIGANDS
ECSP10010034A (en) 2-ANILINOPURIN-8-ONAS AS TTK / MPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
ECSP066365A (en) ANILINO PURINAS REPLACED IN POSITION 6 USEFUL AS RTK INHIBITORS
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
ECSP045473A (en) DERIVATIVES OF 1- (AMINOALQUIL) -3-SULFONYLINDOL AND 1-AMINOALQUIL-3-SULFONYLINDAZOL AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS
UY31748A (en) NEW COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS (CENTRAL NERVOUS SYSTEM)
GT200600159A (en) BENZODIOXAN AND BENZODIOXOLAN DERIVATIVES AND USES OF THE SAME
UY27976A1 (en) HETEROCYCLIC PIPERAZINES SUBSTITUTED FOR THE TREATMENT OF CHICHOPHRENIA
PA8493701A1 (en) COMPOUNDS TO TREAT OBESITY
ECSP045474A (en) 1- (AMINOALQUIL) -3-SULPHONYLAZAINDOLS AS 5-HYDROXYTHYRIPTAMINE-6 LIGANDS
DOP2010000062A (en) CICLOPROPILAMIDE DERIVATIVES
AR054347A1 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
GT200600161A (en) NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS
AR045013A1 (en) METHOD TO TREAT OR PREVENT DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH COMPOUNDS THAT HAVE SELECTIVITY BY THE ALFA -3 SUBUNITY OF THE BENZODIAZEPINAS RECEPTOR
ECSP056011A (en) AZABICICLIC DERIVATIVES OF PIRIDILOXIMETILO AND BENCISOXAZOL
CL2009000599A1 (en) Compounds derived from substituted 4,5-dihydro-1h-pyrazol (4,3-g) benzothiazole; pharmaceutical composition; Useful for the treatment and prevention of cancer, infections, inflammatory and autoimmune diseases, among others.
GT200500332A (en) AZABENZOXAZOLES FOR THE TREATMENT OF CNS DISORDERS
DOP2003000587A (en) Ss3-ADRENERGIC RECEIVER AGONISTS
UY29790A1 (en) DIARILOIMIDAZOLA-4-CARBOXAMID SALTS, COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCESSES AND APPLICATIONS
GT200600130A (en) TETRAHYDROPIRIDOAZEPIN-8-ONAS AND RELATED COMPOUNDS FOR THE TREATMENT OF CHICHOPHRENIA
SV2006002192A (en) AMIDAS OF ACID 5 AND 6-AMINOALQUIL INDOL-2-CARBOXILICO 3-SUBSTITUTES AND RELATED ANALOGS AS INHIBITORS OF CASEINA CINASA IE
UY29712A1 (en) PIPERIDINE DERIVATIVE SALT, PHARMACEUTICAL COMPOSITION CONTAINING IT AND APPLICATIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure